Truestar Enterprise Private Limited

Truestar Enterprise Private Limited is a privately held pharmaceutical company established on September 27, 2019, in Malad West, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999MH2019PTC331077 and is classified as a non-government company. Its authorized and paid-up capital is ₹200,000.

The registered office is located at Office No. 807, 8th Floor, Jaswanti Allied Business Premises CSL, Kachpada, Ramchandra Lane Extension, Malad West, Maharashtra, 400064, India. As of March 31, 2024, the company reported a significant 47.93% increase in total revenue compared to the previous fiscal year, indicating robust growth.

Specific details regarding Truestar Enterprise Private Limited's manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's export data indicates a focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs. This suggests that the manufacturing operations are likely tailored to produce these dosage forms.

The leadership team of Truestar Enterprise Private Limited comprises several directors:

• Dharmesh Gunvantrai Vora: Director, appointed on April 1, 2020.
• Chirag Deepak Dedhia: Additional Director, appointed on October 17, 2024.
• Manisha Arvind Sharma: Additional Director, appointed on October 17, 2024.
• Pooja Mehul Vora: Additional Director, appointed on March 19, 2025.
• Devi Charan Yadav: Additional Director, appointed on March 19, 2025.

These appointments reflect the company's commitment to strengthening its leadership team to support its growth and strategic objectives.

Truestar Enterprise Private Limited's export data indicates shipments to various countries, including Benin, Ghana, and Chad. However, specific information regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan is not publicly available. The company's focus appears to be on markets in Africa and the Middle East, as evidenced by its export destinations.

The company's export activities in Africa, particularly in countries like Benin, Ghana, and Chad, suggest a strategic focus on emerging markets. While specific details about WHO prequalification are not available, the company's engagement in these regions indicates an interest in expanding its footprint in developing markets.

Truestar Enterprise Private Limited's export data reveals a concentration in specific markets, notably in Africa. This focus suggests a strategic approach to penetrate emerging markets, potentially reducing exposure to risks associated with over-diversification. The company's future direction may involve expanding its geographic reach to mitigate concentration risks.

Specific information regarding Truestar Enterprise Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no current market presence in the U.S.

There is no publicly available information confirming whether Truestar Enterprise Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The company's export data does not provide insights into its compliance with these international standards.

Specific details regarding Truestar Enterprise Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not offer insights into its regulatory standing within India.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts associated with Truestar Enterprise Private Limited. The company's export data does not indicate any regulatory challenges or compliance issues.

Truestar Enterprise Private Limited operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. While specific competitors are not identified, the company's export data suggests that it faces competition from other pharmaceutical exporters targeting similar markets, particularly in Africa. The company's market share in its top products indicates a competitive presence in its chosen export destinations.

Truestar Enterprise Private Limited's focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, differentiates it from competitors that may focus on raw APIs or bulk drugs. Its strategic focus on specific export markets, particularly in Africa, allows for tailored marketing and distribution strategies.

The company's current strategic direction appears to be centered on exporting finished pharmaceutical formulations to select international markets. While there is no publicly available information regarding its future outlook, the company's growth in revenue and profitability suggests a positive trajectory. Future strategies may involve expanding its product portfolio and exploring new markets to enhance its global presence.

Truestar Enterprise Private Limited's export data indicates a consistent volume of shipments, primarily focusing on finished pharmaceutical formulations. The company's engagement with multiple buyers across different countries suggests reliability and a stable supply chain. However, specific indicators of supplier reliability, such as on-time delivery rates or quality compliance records, are not publicly available.

Importers should verify the following certifications when considering Truestar Enterprise Private Limited as a supplier:

• FDA Registration: To confirm compliance with U.S. regulatory standards.
• WHO-GMP Certification: To ensure adherence to World Health Organization Good Manufacturing Practices.
• EU GMP Certification: To verify compliance with European Union Good Manufacturing Practices.
• ISO Certifications: To assess quality management and other relevant standards.

These certifications can typically be verified through official regulatory bodies or the company's official communications.

When conducting due diligence on Truestar Enterprise Private Limited, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's certifications and approvals from relevant regulatory bodies.
• Assess Financial Health: Review financial statements to evaluate profitability and revenue growth.
• Evaluate Supply Chain Reliability: Assess the company's track record in fulfilling export orders and maintaining product quality.
• Check for Regulatory Actions: Investigate any past or ongoing regulatory issues or compliance violations.

Be cautious of red flags such as inconsistent financial records, lack of transparency in operations, or unresolved regulatory issues. Recommended pre-order checks include requesting recent financial statements, verifying certifications, and seeking references from previous clients or partners.